ANNOVIS BIO, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.67 USD | +2.62% |
|
-0.15% | -64.71% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 51.96 | 142.4 | 109.6 | 191.9 | 72.61 | - | - |
| Enterprise Value (EV) 1 | 51.96 | 142.4 | 109.6 | 186.1 | -25.09 | 21.61 | -19.99 |
| P/E ratio | -8.67 x | -9.25 x | -4.33 x | -3 x | -4.62 x | -3.16 x | -4.23 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | 8.85 x |
| EV / Revenue | - | - | - | - | - | - | -2.43 x |
| EV / EBITDA | - | - | - | -4.13 x | 0.95 x | -0.49 x | 0.31 x |
| EV / FCF | - | - | - | -4.66 x | 1.06 x | -0.46 x | 0.34 x |
| FCF Yield | - | - | - | -21.5% | 94.1% | -216% | 292% |
| Price to Book | - | - | - | -21.8 x | 1.34 x | 3.48 x | 2.22 x |
| Nbr of stocks (in thousands) | 6,892 | 8,101 | 8,164 | 10,262 | 11,171 | - | - |
| Reference price 2 | 7.540 | 17.58 | 13.43 | 18.70 | 6.500 | 6.500 | 6.500 |
| Announcement Date | 3/3/21 | 3/2/22 | 3/31/23 | 3/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | 8.209 |
| EBITDA 1 | - | - | - | -45.04 | -26.5 | -44 | -64 |
| EBIT 1 | - | -14.54 | -25.51 | -45.04 | -25.6 | -43.69 | -46.65 |
| Operating Margin | - | - | - | - | - | - | -568.32% |
| Earnings before Tax (EBT) 1 | - | -14.49 | -25.33 | -56.2 | -20.79 | -49.24 | -68.13 |
| Net income 1 | -5.462 | -14.49 | -25.33 | -56.2 | -18.55 | -49.22 | -68.11 |
| Net margin | - | - | - | - | - | - | -829.66% |
| EPS 2 | -0.8700 | -1.900 | -3.100 | -6.230 | -1.407 | -2.060 | -1.537 |
| Free Cash Flow 1 | - | - | - | -39.97 | -23.6 | -46.7 | -58.4 |
| FCF margin | - | - | - | - | - | - | -711.41% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 3/3/21 | 3/2/22 | 3/31/23 | 3/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA 1 | - | - | - | - | - | - | - | - | -10.44 | -7.81 | -3.9 | -3.9 | -10.9 |
| EBIT 1 | -5.92 | -5.914 | -8.754 | -7.674 | -3.169 | -9.97 | -9.76 | -14.86 | -10.44 | -7.81 | -5.592 | -5.083 | -7.119 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -5.915 | -5.894 | -8.718 | -7.621 | -3.095 | -9.737 | -9.537 | -14.72 | -22.21 | -1.067 | -5.57 | -5.022 | -6.883 |
| Net income 1 | -5.915 | -5.894 | -8.7 | -7.621 | -3.095 | -9.737 | -9.537 | -14.72 | -22.21 | -1.067 | -5.57 | -5.022 | -6.883 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.7500 | -0.7200 | -1.070 | -0.9300 | -0.3800 | -1.190 | -1.070 | -1.630 | -2.330 | -0.1000 | -0.4733 | -0.2933 | -0.3200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/2/22 | 5/4/22 | 8/8/22 | 11/8/22 | 3/31/23 | 5/10/23 | 8/14/23 | 11/8/23 | 3/29/24 | 5/10/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | - | 5.75 | 97.7 | 51 | 92.6 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | -40 | -23.6 | -46.7 | -58.4 |
| ROE (net income / shareholders' equity) | - | - | - | - | -47.5% | -62.1% | -87.9% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | - | - | -0.8600 | 4.840 | 1.870 | 2.930 |
| Cash Flow per Share 2 | - | - | - | -4.430 | -1.200 | -1.590 | -1.740 |
| Capex 1 | - | - | - | - | 0.8 | 2 | 2 |
| Capex / Sales | - | - | - | - | - | - | 24.36% |
| Announcement Date | 3/3/21 | 3/2/22 | 3/31/23 | 3/29/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
6.5
USD
Average target price
40.33
USD
Spread / Average Target
+520.51%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -64.71% | 72.61M | |
| +18.29% | 125B | |
| +15.43% | 108B | |
| -6.68% | 23.64B | |
| +2.39% | 22.39B | |
| -12.11% | 17.78B | |
| -41.64% | 16.43B | |
| -13.86% | 16.34B | |
| +0.41% | 13.56B | |
| +24.61% | 11.59B |
- Stock Market
- Equities
- ANVS Stock
- Financials Annovis Bio, Inc.
